Dan Ziegler

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1895600/publications.pdf

Version: 2024-02-01

132 papers	14,952 citations	30070 54 h-index	18647 119 g-index
146 all docs	146 docs citations	146 times ranked	11844 citing authors

#	Article	IF	Citations
1	Diabetic Neuropathies. Diabetes Care, 2005, 28, 956-962.	8.6	1,599
2	Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care, 2017, 40, 136-154.	8.6	1,452
3	Diabetic Cardiovascular Autonomic Neuropathy. Circulation, 2007, 115, 387-397.	1.6	1,062
4	Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes/Metabolism Research and Reviews, 2011, 27, 639-653.	4.0	675
5	Oral Treatment With Î±-Lipoic Acid Improves Symptomatic Diabetic Polyneuropathy. Diabetes Care, 2006, 29, 2365-2370.	8.6	491
6	Intraepidermal nerve fiber density at the distal leg: a worldwide normative reference study. Journal of the Peripheral Nervous System, 2010, 15, 202-207.	3.1	462
7	Value of quantitative sensory testing in neurological and pain disorders: NeuPSIG consensus. Pain, 2013, 154, 1807-1819.	4.2	428
8	Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nature Medicine, 2012, 18, 926-933.	30.7	414
9	Assessment of Cardiovascular Autonomic Function: Ageâ€related Normal Ranges and Reproducibility of Spectral Analysis, Vector Analysis, and Standard Tests of Heart Rate Variation and Blood Pressure Responses. Diabetic Medicine, 1992, 9, 166-175.	2.3	365
10	Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes and Endocrinology,the, 2019, 7, 684-694.	11.4	364
11	Prevalence of Polyneuropathy in Pre-Diabetes and Diabetes Is Associated With Abdominal Obesity and Macroangiopathy. Diabetes Care, 2008, 31, 464-469.	8.6	346
12	The Sensory Symptoms of Diabetic Polyneuropathy Are Improved With Î±-Lipoic Acid. Diabetes Care, 2003, 26, 770-776.	8.6	328
13	Efficacy and Safety of Antioxidant Treatment With Î±-Lipoic Acid Over 4 Years in Diabetic Polyneuropathy. Diabetes Care, 2011, 34, 2054-2060.	8.6	318
14	Early Detection of Nerve Fiber Loss by Corneal Confocal Microscopy and Skin Biopsy in Recently Diagnosed Type 2 Diabetes. Diabetes, 2014, 63, 2454-2463.	0.6	270
15	Diabetic cardiovascular autonomic neuropathy: Prognosis, diagnosis and treatment. Diabetes/metabolism Reviews, 1994, 10, 339-383.	0.3	234
16	Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations. Pain, 2012, 153, 1148-1158.	4.2	227
17	Neuropathic Pain in Diabetes, Prediabetes and Normal Glucose Tolerance: The MONICA/KORA Augsburg Surveys S2 and S3. Pain Medicine, 2009, 10, 393-400.	1.9	201
18	Prediction of Mortality Using Measures of Cardiac Autonomic Dysfunction in the Diabetic and Nondiabetic Population. Diabetes Care, 2008, 31, 556-561.	8.6	194

#	Article	IF	Citations
19	Neuropathy in prediabetes: does the clock start ticking early?. Nature Reviews Endocrinology, 2011, 7, 682-690.	9.6	171
20	Epidemiology of polyneuropathy in diabetes and prediabetes. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 126, 3-22.	1.8	166
21	New perspectives on the management of diabetic peripheral neuropathic pain. Diabetes and Vascular Disease Research, 2006, 3, 108-119.	2.0	164
22	Risk Factors and Comorbidities in Diabetic Neuropathy: An Update 2015. Review of Diabetic Studies, 2015, 12, 48-62.	1.3	150
23	Normative Values for Corneal Nerve Morphology Assessed Using Corneal Confocal Microscopy: A Multinational Normative Data Set. Diabetes Care, 2015, 38, 838-843.	8.6	150
24	Oxidative Stress and Antioxidant Defense in Relation to the Severity of Diabetic Polyneuropathy and Cardiovascular Autonomic Neuropathy. Diabetes Care, 2004, 27, 2178-2183.	8.6	146
25	Emerging Biomarkers, Tools, and Treatments for Diabetic Polyneuropathy. Endocrine Reviews, 2019, 40, 153-192.	20.1	140
26	Methods of investigation for cardiac autonomic dysfunction in human research studies. Diabetes/Metabolism Research and Reviews, 2011, 27, 654-664.	4.0	139
27	Efficacy of Î±-lipoic acid in diabetic neuropathy. Expert Opinion on Pharmacotherapy, 2014, 15, 2721-2731.	1.8	139
28	Novel pathogenic pathways in diabetic neuropathy. Trends in Neurosciences, 2013, 36, 439-449.	8.6	128
29	Painful diabetic neuropathy: treatment and future aspects. Diabetes/Metabolism Research and Reviews, 2008, 24, S52-S57.	4.0	126
30	Thioctic Acid for Patients with Symptomatic Diabetic Polyneuropathy. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2004, 3, 173-189.	1.8	115
31	Duloxetine for the Management of Diabetic Peripheral Neuropathic Pain: Evidence-Based Findings from Post Hoc Analysis of Three Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Studies. Clinical Therapeutics, 2007, 29, 2536-2546.	2.5	115
32	Challenges in Design of Multicenter Trials: End points assessed longitudinally for change and monotonicity. Diabetes Care, 2007, 30, 2619-2625.	8.6	109
33	Cohort profile: the German Diabetes Study (GDS). Cardiovascular Diabetology, 2016, 15, 59.	6.8	97
34	Subclinical Inflammation and Diabetic Polyneuropathy. Diabetes Care, 2009, 32, 680-682.	8.6	92
35	Residual microvascular risk in diabetes: unmet needs and future directions. Nature Reviews Endocrinology, 2010, 6, 19-25.	9.6	92
36	Older Subjects With Diabetes and Prediabetes Are Frequently Unaware of Having Distal Sensorimotor Polyneuropathy. Diabetes Care, 2013, 36, 1141-1146.	8.6	89

#	Article	IF	Citations
37	Proinflammatory Cytokines Predict the Incidence and Progression of Distal Sensorimotor Polyneuropathy: KORA F4/FF4 Study. Diabetes Care, 2017, 40, 569-576.	8.6	88
38	Time- and frequency-domain estimation of early diabetic cardiovascular autonomic neuropathy. Clinical Autonomic Research, 2001, 11, 369-376.	2.5	86
39	Increased prevalence of cardiac autonomic dysfunction at different degrees of glucose intolerance in the general population: the KORA S4 survey. Diabetologia, 2015, 58, 1118-1128.	6.3	85
40	Efficacy and Safety of Lacosamide in Painful Diabetic Neuropathy. Diabetes Care, 2010, 33, 839-841.	8.6	83
41	Statement of Retraction. Diabetes Care, 2008, 31, S255-S255.	8.6	82
42	Neuropathy: The Crystal Ball for Cardiovascular Disease?. Diabetes Care, 2010, 33, 1688-1690.	8.6	78
43	Association of Subclinical Inflammation With Polyneuropathy in the Older Population. Diabetes Care, 2013, 36, 3663-3670.	8.6	76
44	Prevalence of Cardiovascular Autonomic Dysfunction Assessed by Spectral Analysis and Standard Tests of Heart-Rate Variation in Newly Diagnosed IDDM Patients. Diabetes Care, 1992, 15, 908-911.	8.6	75
45	Painful Diabetic Neuropathy. Diabetes Care, 2009, 32, S414-S419.	8.6	75
46	From guideline to patient: a review of recent recommendations for pharmacotherapy of painful diabetic neuropathy. Journal of Diabetes and Its Complications, 2015, 29, 146-156.	2.3	75
47	Prevalence and risk factors of neuropathic pain in survivors of myocardial infarction with preâ€diabetes and diabetes. The KORA Myocardial Infarction Registry. European Journal of Pain, 2009, 13, 582-587.	2.8	74
48	A randomized double-blind, placebo-, and active-controlled study of T-type calcium channel blocker ABT-639 in patients with diabetic peripheral neuropathic pain. Pain, 2015, 156, 2013-2020.	4.2	74
49	Treatment of Symptomatic Polyneuropathy With Actovegin in Type 2 Diabetic Patients. Diabetes Care, 2009, 32, 1479-1484.	8.6	73
50	Impact of Disease Characteristics on the Efficacy of Duloxetine in Diabetic Peripheral Neuropathic Pain. Diabetes Care, 2007, 30, 664-669.	8.6	72
51	Whither pathogenetic treatments for diabetic polyneuropathy?. Diabetes/Metabolism Research and Reviews, 2013, 29, 327-333.	4.0	68
52	Predictors of improvement and progression of diabetic polyneuropathy following treatment with Î±-lipoic acid for 4years in the NATHAN 1 trial. Journal of Diabetes and Its Complications, 2016, 30, 350-356.	2.3	66
53	Screening, diagnosis and management of diabetic sensorimotor polyneuropathy in clinical practice: International expert consensus recommendations. Diabetes Research and Clinical Practice, 2022, 186, 109063.	2.8	66
54	New diagnostic tests for diabetic distal symmetric polyneuropathy. Journal of Diabetes and Its Complications, 2011, 25, 44-51.	2.3	64

#	Article	IF	Citations
55	General and Abdominal Obesity and Incident Distal Sensorimotor Polyneuropathy: Insights Into Inflammatory Biomarkers as Potential Mediators in the KORA F4/FF4 Cohort. Diabetes Care, 2019, 42, 240-247.	8.6	64
56	Current concepts in the management of diabetic polyneuropathy. Journal of Diabetes Investigation, 2021, 12, 464-475.	2.4	56
57	Postchallenge Hyperglycemia Is Positively Associated With Diabetic Polyneuropathy. Diabetes Care, 2012, 35, 1891-1893.	8.6	55
58	Prediabetic Neuropathy: Does It Exist?. Current Diabetes Reports, 2012, 12, 376-383.	4.2	54
59	Patterns of cutaneous nerve fibre loss and regeneration in type 2 diabetes with painful and painless polyneuropathy. Diabetologia, 2017, 60, 2495-2503.	6.3	54
60	Treatment of Diabetic Polyneuropathy: Update 2006. Annals of the New York Academy of Sciences, 2006, 1084, 250-266.	3.8	53
61	Validation of a Novel Screening Device (NeuroQuick) for Quantitative Assessment of Small Nerve Fiber Dysfunction as an Early Feature of Diabetic Polyneuropathy. Diabetes Care, 2005, 28, 1169-1174.	8.6	52
62	Corneal confocal microscopy: Recent progress in the evaluation of diabetic neuropathy. Journal of Diabetes Investigation, 2015, 6, 381-389.	2.4	51
63	Inflammatory markers are associated with cardiac autonomic dysfunction in recent-onset type 2 diabetes. Heart, 2017, 103, 63-70.	2.9	51
64	Neuroprotective and Anti-Oxidative Effects of the Hemodialysate Actovegin on Primary Rat Neurons in Vitro. NeuroMolecular Medicine, 2011, 13, 266-274.	3.4	50
65	Near-normoglycaemia and development of neuropathy: a 24-year prospective study from diagnosis of type 1 diabetes. BMJ Open, 2015, 5, e006559.	1.9	47
66	Painful and painless neuropathies are distinct and largely undiagnosed entities in subjects participating in an educational initiative (PROTECT study). Diabetes Research and Clinical Practice, 2018, 139, 147-154.	2.8	45
67	Current Concepts in the Management of Diabetic Polyneuropathy. Current Diabetes Reviews, 2011, 7, 208-220.	1.3	44
68	NADPH Oxidase Inhibition: Preclinical and Clinical Studies in Diabetic Complications. Antioxidants and Redox Signaling, 2020, 33, 415-434.	5.4	41
69	Adiponectin, markers of subclinical inflammation and nerve conduction in individuals with recently diagnosed type 1 and type 2 diabetes. European Journal of Endocrinology, 2016, 174, 433-443.	3.7	38
70	A gain-of-function sodium channelÎ²2-subunit mutation in painful diabetic neuropathy. Molecular Pain, 2019, 15, 174480691984980.	2.1	38
71	High prevalence of diagnosed and undiagnosed polyneuropathy in subjects with and without diabetes participating in a nationwide educational initiative (PROTECT study). Journal of Diabetes and Its Complications, 2015, 29, 998-1002.	2.3	36
72	Differential Association Between Biomarkers of Subclinical Inflammation and Painful Polyneuropathy: Results From the KORA F4 Study. Diabetes Care, 2015, 38, 91-96.	8.6	36

#	Article	IF	Citations
73	Oxidative stress predicts progression of peripheral and cardiac autonomic nerve dysfunction over 6Âyears in diabetic patients. Acta Diabetologica, 2015, 52, 65-72.	2.5	36
74	A Systemic Inflammatory Signature Reflecting Cross Talk Between Innate and Adaptive Immunity Is Associated With Incident Polyneuropathy: KORA F4/FF4 Study. Diabetes, 2018, 67, 2434-2442.	0.6	36
75	New vistas in the diagnosis of diabetic polyneuropathy. Endocrine, 2014, 47, 690-698.	2.3	35
76	Novel Insights into Sensorimotor and Cardiovascular Autonomic Neuropathy from Recent-Onset Diabetes and Population-Based Cohorts. Trends in Endocrinology and Metabolism, 2019, 30, 286-298.	7.1	35
77	The Role of Sodium Channels in Painful Diabetic and Idiopathic Neuropathy. Current Diabetes Reports, 2014, 14, 538.	4.2	33
78	Emerging drugs for diabetic peripheral neuropathy and neuropathic pain. Expert Opinion on Emerging Drugs, 2016, 21, 393-407.	2.4	32
79	Lower serum extracellular superoxide dismutase levels are associated with polyneuropathy in recent-onset diabetes. Experimental and Molecular Medicine, 2017, 49, e394-e394.	7.7	29
80	Association of Lower Cardiovagal Tone and Baroreflex Sensitivity With Higher Liver Fat Content Early in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1130-1138.	3.6	28
81	Effectiveness of Duloxetine Compared With Pregabalin and Gabapentin in Diabetic Peripheral Neuropathic Pain. Clinical Journal of Pain, 2014, 30, 875-885.	1.9	27
82	Treatment withÎ±-Lipoic Acid over 16 Weeks in Type 2 Diabetic Patients with Symptomatic Polyneuropathy Who Responded to Initial 4-Week High-Dose Loading. Journal of Diabetes Research, 2015, 2015, 1-8.	2.3	27
83	Effect of Low-Energy Diets Differing in Fiber, Red Meat, and Coffee Intake on Cardiac Autonomic Function in Obese Individuals With Type 2 Diabetes. Diabetes Care, 2015, 38, 1750-1757.	8.6	27
84	Differential Patterns of Impaired Cardiorespiratory Fitness and Cardiac Autonomic Dysfunction in Recently Diagnosed Type 1 and Type 2 Diabetes. Diabetes Care, 2017, 40, 246-252.	8.6	26
85	Differential associations of lower cardiac vagal tone with insulin resistance and insulin secretion in recently diagnosed type 1 and type 2 diabetes. Metabolism: Clinical and Experimental, 2018, 79, 1-9.	3.4	25
86	Neuron-specific biomarkers predict hypo- and hyperalgesia in individuals with diabetic peripheral neuropathy. Diabetologia, 2021, 64, 2843-2855.	6.3	25
87	Clinical trials for drugs against diabetic neuropathy: Can we combine scientific needs with clinical practicalities?. International Review of Neurobiology, 2002, 50, 431-463.	2.0	22
88	Association of transketolase polymorphisms with measures of polyneuropathy in patients with recently diagnosed diabetes. Diabetes/Metabolism Research and Reviews, 2017, 33, e2811.	4.0	22
89	Cardiorespiratory Fitness and Cardiac Autonomic Function in Diabetes. Current Diabetes Reports, 2017, 17, 125.	4.2	21
90	Association of cardiac autonomic dysfunction with higher levels of plasma lipid metabolites in recent-onset type 2 diabetes. Diabetologia, 2021, 64, 458-468.	6.3	20

#	Article	IF	Citations
91	Enantiomer-selective pharmacokinetics, oral bioavailability, and sex effects of various alpha-lipoic acid dosage forms. Clinical Pharmacology: Advances and Applications, 2014, 6, 195.	1.2	18
92	American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on Testing for Autonomic And Somatic Nerve Dysfunction. Endocrine Practice, 2017, 23, 1472-1478.	2.1	18
93	Myeloperoxidase, superoxide dismutaseâ€3, cardiometabolic risk factors, and distal sensorimotor polyneuropathy: The KORA F4/FF4 study. Diabetes/Metabolism Research and Reviews, 2018, 34, e3000.	4.0	18
94	Pronounced Reduction of Cutaneous Langerhans Cell Density in Recently Diagnosed Type 2 Diabetes. Diabetes, 2014, 63, 1148-1153.	0.6	17
95	Neuropathy in Diabetes: â€œOne Cannot Begin It Too Soonâ€• Angiology, 2018, 69, 752-754.	1.8	17
96	Constant hepatic ATP concentrations during prolonged fasting and absence of effects of Cerbomed NemosÂ® on parasympathetic tone and hepatic energy metabolism. Molecular Metabolism, 2018, 7, 71-79.	6.5	17
97	Neuropathic pain is not adequately treated in the older general population: Results from the KORA F4 survey. Pharmacoepidemiology and Drug Safety, 2018, 27, 806-814.	1.9	16
98	Impairment in Baroreflex Sensitivity in Recent-Onset Type 2 Diabetes Without Progression Over 5 Years. Diabetes, 2020, 69, 1011-1019.	0.6	16
99	The Role of Biofactors in Diabetic Microvascular Complications. Current Diabetes Reviews, 2022, 18, .	1.3	16
100	Impact of comorbidities on pharmacotherapy of painful diabetic neuropathy in clinical practice. Journal of Diabetes and Its Complications, 2014, 28, 698-704.	2.3	15
101	Predictors of response to treatment with actovegin for 6 months in patients with type 2 diabetes and symptomatic polyneuropathy. Journal of Diabetes and Its Complications, 2017, 31, 1181-1187.	2.3	15
102	Diabetic Neuropathy. Experimental and Clinical Endocrinology and Diabetes, 2021, 129, S70-S81.	1.2	14
103	Progression and regression of nerve fibre pathology and dysfunction early in diabetes over 5 years. Brain, 2021, 144, 3251-3263.	7.6	14
104	Differences in the prevalence of erectile dysfunction between novel subgroups of recent-onset diabetes. Diabetologia, 2022, 65, 552-562.	6.3	14
105	Expansion and Impaired Mitochondrial Efficiency of Deep Subcutaneous Adipose Tissue in Recent-Onset Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1331-e1343.	3.6	13
106	Association of Long-Term Air Pollution with Prevalence and Incidence of Distal Sensorimotor Polyneuropathy: KORA F4/FF4 Study. Environmental Health Perspectives, 2020, 128, 127013.	6.0	13
107	Augmented Corneal Nerve Fiber Branching in Painful Compared With Painless Diabetic Neuropathy. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 6220-6228.	3.6	12
108	Polyneuropathy is inadequately treated despite increasing symptom intensity in individuals with and without diabetes (PROTECT followâ€up study). Journal of Diabetes Investigation, 2020, 11, 1272-1277.	2.4	12

#	Article	IF	Citations
109	Deficits in systemic biomarkers of neuroinflammation and growth factors promoting nerve regeneration in patients with type 2 diabetes and polyneuropathy. BMJ Open Diabetes Research and Care, 2019, 7, e000752.	2.8	12
110	Spatial analysis improves the detection of early corneal nerve fiber loss in patients with recently diagnosed type 2 diabetes. PLoS ONE, 2017, 12, e0173832.	2.5	12
111	Cumulative long-term recurrence of diabetic foot ulcers in two cohorts from centres in Germany and the Czech Republic. Diabetes Research and Clinical Practice, 2021, 172, 108621.	2.8	11
112	Double-blind, randomized, placebo-controlled crossover trial of alpha-lipoic acid for the treatment of fibromyalgia pain: the IMPALA trial. Pain, 2021, 162, 561-568.	4.2	10
113	Differential Patterns and Determinants of Cardiac Autonomic Nerve Dysfunction during Endotoxemia and Oral Fat Load in Humans. PLoS ONE, 2015, 10, e0124242.	2.5	10
114	Overexpression of cutaneous mitochondrial superoxide dismutase in recent-onset type 2 diabetes. Diabetologia, 2015, 58, 1621-1625.	6.3	9
115	BOND study: a randomised double-blind, placebo-controlled trial over 12 months to assess the effects of benfotiamine on morphometric, neurophysiological and clinical measures in patients with type 2 diabetes with symptomatic polyneuropathy. BMJ Open, 2022, 12, e057142.	1.9	9
116	Peripheral Ion Channel Gene Screening in Painful- and Painless-Diabetic Neuropathy. International Journal of Molecular Sciences, 2022, 23, 7190.	4.1	9
117	Early detection of neuropathy in leprosy: a comparison of five tests for field settings. Infectious Diseases of Poverty, 2017, 6, 115.	3.7	8
118	High-intensity interval training for 12Âweeks improves cardiovascular autonomic function but not somatosensory nerve function and structure in overweight men with type 2 diabetes. Diabetologia, 2022, 65, 1048-1057.	6.3	8
119	German Diabetes Study â€“ Baseline data of retinal layer thickness measured by <scp>SD</scp>â€<scp>OCT</scp> in early diabetes mellitus. Acta Ophthalmologica, 2019, 97, e303-e307.	1.1	7
120	Interaction between magnesium and methylglyoxal in diabetic polyneuropathy and neuronal models. Molecular Metabolism, 2021, 43, 101114.	6.5	7
121	Diagnostic Tools, Biomarkers, and Treatments in Diabetic polyneuropathy and Cardiovascular Autonomic Neuropathy. Current Diabetes Reviews, 2022, 18, .	1.3	6
122	Management of painful diabetic neuropathy: What is new or in the pipeline for 2007?. Current Diabetes Reports, 2007, 7, 409-415.	4.2	5
123	Patient Expectations in the Treatment of Painful Diabetic Polyneuropathy: Results from a Non-Interventional Study. Pain Medicine, 2014, 15, 671-681.	1.9	5
124	Treatment with benfotiamine in patients with diabetic sensorimotor polyneuropathy: A double-blind, randomized, placebo-controlled, parallel group pilot study over 12â€¯months. Journal of Diabetes and Its Complications, 2020, 34, 107757.	2.3	5
125	Innovations in the Management of Musculoskeletal Pain With Alpha-Lipoic Acid (IMPALA Trial): Study protocol for a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of Alpha-Lipoic Acid for the Treatment of Fibromyalgia Pain. JMIR Research Protocols, 2017, 6, e41.	1.0	5
126	Comment on: Fraser et al. The Effects of Long-Term Oral Benfotiamine Supplementation on Peripheral Nerve Function and Inflammatory Markers in Patients With Type 1 Diabetes: A 24-Month, Double-Blind, Randomized, Placebo-Controlled Trial. Diabetes Care 2012;35:1095-1097. Diabetes Care, 2012, 35, e79-e79.	8.6	4

#	Article	IF	Citations
127	Associations of cells from both innate and adaptive immunity with lower nerve conduction velocity: the Maastricht Study. BMJ Open Diabetes Research and Care, 2021, 9, e001698.	2.8	4
128	Comment on Haussleiter et al.: NeuroQuick â€“ A novel bedside test for small fiber neuropathy?. European Journal of Pain, 2009, 13, 217-217.	2.8	2
129	Association of persistent organic pollutants with sensorimotor neuropathy in participants with and without diabetes or prediabetes: Results from the population-based KORA FF4 study. International Journal of Hygiene and Environmental Health, 2021, 235, 113752.	4.3	2
130	Effect of obesity on the associations of 25-hydroxyvitamin D with prevalent and incident distal sensorimotor polyneuropathy: population-based KORA F4/FF4 study. International Journal of Obesity, 2022, 46, 1366-1374.	3.4	2
131	Response to research letter in relation to paper by Bongaerts et al., A Clinical Screening Score for Diabetic Polyneuropathy: KORA F4 and AusDiab Studies (A single question screening test for the) Tj ETQq1 1 0.784314 rgBT /Overloc	2.3	1
132	Diabetic Peripheral Neuropathy and Sexual Dysfunction. , 2007, , 277-312.		0